Female Fertility Drugs Market size valued at USD 3.28 billion in 2020 is expected to reach $6.4 billion in 2027, at a CAGR of 6.3% during the forecast period 2021-2027. Female fertility drugs are the agents used to improve reproductive health in women and act to stimulate the follicle development of the ovary. Women’s fertility drugs are extremely effective and the first treatment option to overcome infertility. Fertility drugs act by direct stimulation of ovaries or balancing the hormone levels. Infertility in women occurs due to hypothalamic dysfunction, excessive prolactin, pelvic inflammatory diseases, premature ovarian insufficiency, and polycystic ovary syndrome among others. The major symptom associated with infertility is an absence or irregular menstrual cycle. The female fertility drugs market is growing at a significant CAGR with several local and international players operating in infertility treatment. The prevalence of infertility is increasing due to changes in lifestyles such as smoking and alcohol consumption. According to World Health Organization, approximately 60-80 Mn couples are suffering from infertility around the world. Moreover, acquisitions & mergers, collaborations, product approvals, and product launchings are the strategies followed by the companies for increasing their market revenue share in the female fertility drugs market. For instance, in March 2014, Ferring Pharmaceuticals received FDA approval for the combination of Menopur and Bravelle injection used in the treatment of infertility.